Comparative Review of Alzheimer Therapeutics Coverage Across 3 Major Health Plans
How Are Health Plans Really Covering Alzheimer’s Treatments in 2026?
Alzheimer’s disease treatment is entering a new—and highly complex—era. With the rise of disease-modifying therapies, increasing scrutiny around cost and clinical value, and evolving payer policies, understanding real-world formulary access has never been more critical.
In this exclusive Formulary Frontlines report, we break down how 3 major health plans—BCBS, Cigna, and UnitedHealthcare—are approaching coverage across key Alzheimer therapy classes. From tier placement and prior authorization requirements to access barriers and cost-sharing implications, this analysis reveals where coverage is expanding—and where it remains restricted.
Key Insights
-
Coverage isn’t created equal: Major health plans show meaningful variation in how Alzheimer therapies are tiered and managed
-
Utilization management drives access: Prior authorization, quantity limits, and dispensing limits significantly impact patient access and speed to therapy
-
Generics dominate—but strategy differs: While all plans favor generic therapies, approaches range from open access (Cigna) to highly managed frameworks (UnitedHealthcare)
-
Notable access gaps exist: Some plans exclude or restrict entire therapy classes, creating real-world barriers despite clinical availability
-
Cost-sharing still matters: Even when therapies are covered, higher-tier placement can limit affordability and influence utilization
What You’ll Gain
-
A clear, side-by-side view of formulary coverage across three major payers
-
Actionable insights into payer decision-making and access strategy
-
A deeper understanding of how policy translates into real-world patient access
-
Context for how payers may approach emerging, high-cost Alzheimer therapies
-
Data to inform your market access, commercialization, and stakeholder engagement strategies
Even in long-established, largely generic treatment categories, payer decisions are shaping who gets access, how quickly, and at what cost.
Download the full report to get a clear, side-by-side view of Alzheimer’s formulary coverage—and what it means for market access, policy, and patient care.
